CAMBRIDGE, Mass. , Feb. 26, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli , Ph.D., Chairman, President and Chief Executive Officer, Douglas E. Onsi , Chief Financial Officer, and Cynthia Sirard , MD, Vice President, Clinical R
| CAMBRIDGE, Mass., Feb. 26, 2020 /PRNewswire/ -- Leap Therapeutics. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, Douglas E. Onsi, Chief Financial Officer, and Cynthia Sirard, MD, Vice President, Clinical Research & Development, will present a corporate overview at the Cowen 40th Annual Health Care Conference, being held in Boston on March 2-4, 2020. The presentation will be followed by a 30-minute breakout session. Leap Presentation and Breakout Session Details: Cowen 40th Annual Health Care Conference The presentation will be webcast live and may be accessed on the Investors page of the company’s website at https://investors.leaptx.com/, where a replay of the event will also be available for a limited time. About Leap Therapeutics FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include statements regarding expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in future studies, potential for the receipt of future option exercise, milestones or royalty payments from BeiGene, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap Therapeutics’ periodic filings with the SEC, including Leap’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as filed with the SEC on April 1, 2019, and Leap’s Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. CONTACT: Douglas E. Onsi Heather Savelle
SOURCE Leap Therapeutics, Inc. | ||
Company Codes: NASDAQ-NMS:LPTX |
View original content to download multimedia:
